eurolife
network of european universities in life sciences

TRINITY COLLEGE DUBLIN
COLÁISTE NA TRÍONÓIDE
THE UNIVERSITY OF DUBLIN

The Eurolife Distinguished Faculty Lecture Series

Presents:

Immunotherapeutics

Therapy of Established Lesions Caused by High Risk Human Papilloma Virus

by

Cornelis J.M. Melief

**Departments of Immunohematology and Blood Transfusion,
Leiden University Medical Center, and ISA Pharmaceuticals,
Leiden, The Netherlands**

September 16th at 6pm
in the Maxwell Theatre

**Hamilton Building, Trinity College Dublin
(entrance by Nassau St., Lincoln Place Gate)
Followed by Reception
All Welcome**



BRIEF BIOGRAPHY

The work of Cornelis (Kees) Melief has contributed fundamental insights into the cellular and molecular mechanisms governing the generation of cytotoxic T lymphocytes (CTL) responses, the most important adaptive immune response against viruses and tumors. This includes among the first demonstration of the central role played by Dendritic Cells in the activation of immune responses, and the provision of the concept of the "licensing" of professional antigen presenting cell functions by CD4+ T helper cells, required for the optimized induction of CTL responses. Cees Melief has also pioneered the use the of CTL-dependent responses in adoptive immunotherapy of cancer, providing the first evidence that CTLs specific for an oncogene tumor antigen could eradicate large vascularized tumors in mice.

Based on the series of elegant pre-clinical studies, the group of Melief has developed vaccination strategies with synthetic long peptides derived from HPV virus, which led to markedly improved vaccine performance, resulting in the treatment of established high risk papillomavirus-induced tumors in mice and rabbits. These studies led to the development of vaccines for (pre-)malignant high risk HPV16-induced intraepithelial neoplasia in patients with proven clinical efficacy (see Melief & van der Burg, Nat Rev Cancer 8:351, 2008, and Kenter et al. N Engl J Med 361:1838, 2009)